Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 200-205

  Soriano, Vincent ^a   García Gasco, Pilar ^a   Vispo, Eugenia ^a   Ruiz Sancho, Andrés ^a   Blanco, Francisco ^a   Martín Carbonero, Luz ^a   Rodríguez Novoa, Sonia ^a   Morello, Judit ^a   De Mendoza, Carmen ^a   Rivas, Pablo ^a   Barreiro, Pablo ^a   González Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Drug resistance; Dyslipidaemia; Metabolic syndrome; Simplification strategies

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VIREMIA; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; PYRIMIDINONES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 37549038211     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm413     Document Type: Article

References (21)

1. Panel on Clinical Practices for Treatment of HIV Infection convened by the U.S. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents - April 2006. http://AIDSinfo.nih.gov.
2. Bongiovanni M, Bini T, Cicconi P et al. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. AIDS Res Hum Retroviruses 2006; 22: 132-8.
3. Friis-Moller N, Sabin C, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
4. Weber R, Sabin C, Friis-Moller N et al. Liver-related deaths in persons infected with HIV: The D:A:D study. Arch Intern Med 2006; 166: 1632-41.
5. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
6. Martinez E, Arnaiz J, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection. N Engl J Med 2003; 349: 1036-46.
7. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
8. Mobius U, Lubach-Ruitman M, Castro-Frenzel B et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hypedipidemia. J Acquir Immune Defic Syndr 2005; 39: 174-80.
9. Stone V. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clin Infect Dis 2001; 33: 865-72.
10. Gatell J, Salmon-Ceron D, Lazzarin A et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week result. Clin Infect Dis 2007; 44: 1484-92.
11. Tribut O, Arvieux C, Michelet C et al. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002; 24: 554-62.
12. Khoo S, Lloyd J, Dalton M et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006; 41: 461-7.
13. Knobel H, Alonso J, Casado J et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA study. AIDS 2002; 16: 605-13.
14. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28: 468-73.
15. Expert panel on detection evaluation treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
16. Murphy R, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS 2003; 17: 2603-14.
17. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-8.
18. Cohen C, Nieto-Cisneros L, Zala C et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial. Curr Med Res Opin 2005; 21: 1683-92.
19. Wood R, Phanuphak P, Cahn P et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36: 684-92.
20. Howard A, Lo Y, Floris-Moore M et al. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007; 21: 633-41.
21. Cooper C, Mills E, Angel J. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 2007; 21 71-6.